[1]
|
Joham, A.E., Norman, R.J., Stener-Victorin, E., et al. (2022) Polycystic Ovary Syndrome. The Lancet Diabetes & En-docrinology, 10, 668-680. https://doi.org/10.1016/S2213-8587(22)00163-2
|
[2]
|
Kakoly, N.S., Earnest, A., Teede, H.J., et al. (2019) The Impact of Obesity on the Incidence of Type 2 Diabetes among Women with Polycystic Ovary Syndrome. Diabetes Care, 42, 560-567. https://doi.org/10.2337/dc18-1738
|
[3]
|
Wekker, V., van Dammen, L., Koning, A., et al. (2020) Long-Term Cardiometabolic Disease Risk in Women with PCOS: A Systematic Review and Meta-Analysis. Human Reproduction Update, 26, 942-960.
https://doi.org/10.1093/humupd/dmaa029
|
[4]
|
Barry, J.A., Azizia, M.M. and Hardiman, P.J. (2014) Risk of En-dometrial, Ovarian and Breast Cancer in Women with Polycystic Ovary Syndrome: A Systematic Review and Me-ta-Analysis. Human Reproduction Update, 20, 748-758.
https://doi.org/10.1093/humupd/dmu012
|
[5]
|
Persson, S., Elenis, E., Turkmen, S., et al. (2021) Higher Risk of Type 2 Diabetes in Women with Hyperandrogenic Polycystic Ovary Syndrome. Fertility and Sterility, 116, 862-871. https://doi.org/10.1016/j.fertnstert.2021.04.018
|
[6]
|
Liu, Q., Tang, B., Zhu, Z., et al. (2022) A Genome-Wide Cross-Trait Analysis Identifies Shared Loci and Causal Relationships of Type 2 Diabetes and Glycaemic Traits with Pol-ycystic Ovary Syndrome. Diabetologia, 65, 1483-1494.
https://doi.org/10.1007/s00125-022-05746-x
|
[7]
|
Escobar-Morreale, H.F. (2018) Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment. Nature Reviews Endocrinology, 14, 270-284. https://doi.org/10.1038/nrendo.2018.24
|
[8]
|
Joo, Y.Y., Actkins, K., Pacheco, J.A., et al. (2020) A Polygenic and Phenotypic Risk Prediction for Polycystic Ovary Syndrome Evaluated by Phenome-Wide Association Studies. The Journal of Clinical Endocrinology & Metabolism, 105, 1918-1936. https://doi.org/10.1210/clinem/dgz326
|
[9]
|
Liu, Q., Zhu, Z., Kraft, P., et al. (2022) Genomic Correlation, Shared Loci, and Causal Relationship between Obesity and Polycystic Ovary Syndrome: A Large-Scale Genome-Wide Cross-Trait Analysis. BMC Medicine, 20, Article No. 66. https://doi.org/10.1186/s12916-022-02238-y
|
[10]
|
Cena, H., Chiovato, L. and Nappi, R.E. (2020) Obesity, Poly-cystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. The Journal of Clinical Endocri-nology & Metabolism, 105, e2695-e2709.
https://doi.org/10.1210/clinem/dgaa285
|
[11]
|
Zhang, H., Wang, W., Zhao, J., et al. (2022) Relationship between Body Composition, Insulin Resistance, and Hormonal Profiles in Women with Polycystic Ovary Syndrome. Frontiers in Endocrinology (Lausanne), 13, Article ID: 1085656. https://doi.org/10.3389/fendo.2022.1085656
|
[12]
|
Glueck, C.J. and Goldenberg, N. (2019) Characteristics of Obesity in Polycystic Ovary Syndrome: Etiology, Treatment, and Genetics. Metabolism, 92, 108-120. https://doi.org/10.1016/j.metabol.2018.11.002
|
[13]
|
Wu, L., Fang, Q., Wang, M., et al. (2022) Effect of Weight Loss on Pregnancy Outcomes, Neuronal-Reproductive- Metabolic Hormones and Gene Expres-sion Profiles in Granulosa Cells in Obese Infertile PCOS Patients Undergoing IVF-ET. Frontiers in Endocrinology (Lausanne), 13, Article ID: 954428. https://doi.org/10.3389/fendo.2022.954428
|
[14]
|
Visser, J.A. (2021) The Im-portance of Metabolic Dysfunction in Polycystic Ovary Syndrome. Nature Reviews Endocrinology, 17, 77-78. https://doi.org/10.1038/s41574-020-00456-z
|
[15]
|
Zeng, X., Xie, Y.J., Liu, Y.T., et al. (2020) Polycystic Ovarian Syndrome: Correlation between Hyperandrogenism, Insulin Resistance and Obesity. Clinica Chimica Acta, 502, 214-221. https://doi.org/10.1016/j.cca.2019.11.003
|
[16]
|
de Medeiros, S.F., Rodgers, R.J. and Norman, R.J. (2021) Adipo-cyte and Steroidogenic Cell Cross-Talk in Polycystic Ovary Syndrome. Human Reproduction Update, 27, 771-796. https://doi.org/10.1093/humupd/dmab004
|
[17]
|
Velazquez, E.M., Mendoza, S., Hamer, T., et al. (1994) Metformin Therapy in Polycystic Ovary Syndrome Reduces Hyperinsulinemia, Insulin Resistance, Hyperandrogenemia, and Systol-ic Blood Pressure, While Facilitating Normal Menses and Pregnancy. Metabolism, 43, 647-654. https://doi.org/10.1016/0026-0495(94)90209-7
|
[18]
|
Lord, J.M., Flight, I.H. and Norman, R.J. (2003) Metformin in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis. BMJ, 327, 951-953. https://doi.org/10.1136/bmj.327.7421.951
|
[19]
|
Li, X., Celotto, S., Pizzol, D., et al. (2021) Metformin and Health Outcomes: An Umbrella Review of Systematic Reviews with Meta-Analyses. European Journal of Clinical Investigation, 51, e13536. https://doi.org/10.1111/eci.13536
|
[20]
|
Garcia-Gomez, E., Gomez-Viais, Y.I., Cruz-Aranda, M.M., et al. (2023) The Effect of Metformin and Carbohydrate-Controlled Diet on DNA Methylation and Gene Expression in the Endometrium of Women with Polycystic Ovary Syndrome. International Journal of Molecular Sciences, 24, Article No. 6857.
https://doi.org/10.3390/ijms24076857
|
[21]
|
Orostica, M.L., Astorga, I., Plaza-Parrochia, F., et al. (2022) Metformin Treatment Regulates the Expression of Molecules Involved in Adiponectin and Insulin Signaling Pathways in Endometria from Women with Obesity-Associated Insulin Resistance and PCOS. International Journal of Molecular Sciences, 23, Article No. 3922.
https://doi.org/10.3390/ijms23073922
|
[22]
|
Lovvik, T.S., Carlsen, S.M., Salvesen, O., et al. (2019) Use of Metfor-min to Treat Pregnant Women with Polycystic Ovary Syndrome (PregMet2): A Randomised, Double-Blind, Place-bo-Controlled Trial. The Lancet Diabetes & Endocrinology, 7, 256-266. https://doi.org/10.1016/S2213-8587(19)30002-6
|
[23]
|
Li, Y., Tan, J., Wang, Q., et al. (2020) Comparing the Indi-vidual Effects of Metformin and Rosiglitazone and Their Combination in Obese Women with Polycystic Ovary Syn-drome: A Randomized Controlled Trial. Fertility and Sterility, 113, 197-204. https://doi.org/10.1016/j.fertnstert.2019.09.011
|
[24]
|
Zhao, H., Wang, D., Xing, C., et al. (2023) Pioglitazone Can Improve Liver Sex Hormone-Binding Globulin Levels and Lipid Metabolism in Polycystic Ovary Syndrome by Regu-lating Hepatocyte Nuclear Factor-4α. The Journal of Steroid Biochemistry and Molecular Biology, 229, Article ID: 106265. https://doi.org/10.1016/j.jsbmb.2023.106265
|
[25]
|
Penna, I.A., Canella, P.R., Reis, R.M., et al. (2005) Acarbose in Obese Patients with Polycystic Ovarian Syndrome: A Double-Blind, Randomized, Placebo-Controlled Study. Human Reproduction, 20, 2396-2401.
https://doi.org/10.1093/humrep/dei104
|
[26]
|
Sonmez, A.S., Yasar, L., Savan, K., et al. (2005) Comparison of the Effects of Acarbose and Metformin Use on Ovulation Rates in Clomiphene Citrate-Resistant Polycystic Ovary Syndrome. Human Reproduction, 20, 175-179.
https://doi.org/10.1093/humrep/deh580
|
[27]
|
Araujo, P.I., Canella, P.R., Vieira, C.S., et al. (2007) Cardiovascular Risk Factors Are Reduced with a Low Dose of Acarbose in Obese Patients with Polycystic Ovary Syndrome. Fertility and Sterility, 88, 519-522.
https://doi.org/10.1016/j.fertnstert.2006.11.073
|
[28]
|
Wang, X., Xu, T., Liu, R., et al. (2021) High-Fiber Diet or Combined with Acarbose Alleviates Heterogeneous Phenotypes of Polycystic Ovary Syndrome by Regulating Gut Mi-crobiota. Frontiers in Endocrinology (Lausanne), 12, Article ID: 806331. https://doi.org/10.3389/fendo.2021.806331
|
[29]
|
Bednarz, K., Kowalczyk, K., Cwynar, M., et al. (2022) The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. International Journal of Molecular Sciences, 23, Article No. 4334. https://doi.org/10.3390/ijms23084334
|
[30]
|
Wu, L.M., Wang, Y.X., Zhan, Y., et al. (2021) Dulaglutide, a Long-Acting GLP-1 Receptor Agonist, Can Improve Hyper-androgenemia and Ovarian Function in DHEA-Induced PCOS Rats. Peptides, 145, Article ID: 170624.
https://doi.org/10.1016/j.peptides.2021.170624
|
[31]
|
Zhang, Y., Lin, Y., Li, G., et al. (2023) Glucagon-Like Pep-tide-1 Receptor Agonists Decrease Hyperinsulinemia and Hyperandrogenemia in Dehydroepiandrosterone-Induced Pol-ycystic Ovary Syndrome Mice and Are Associated with Mitigating Inflammation and Inducing Browning of White Adi-pose Tissuedagger. Biology of Reproduction, 108, 945-959. https://doi.org/10.1093/biolre/ioad032
|
[32]
|
Yang, S., Zhao, L., He, W., et al. (2022) The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-Analysis. Drugs, 82, 1469-1480. https://doi.org/10.1007/s40265-022-01779-z
|
[33]
|
Zhang, Y., Qu, Z., Lu, T., et al. (2023) Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Pol-ycystic Ovary Syndrome: A Randomized Controlled Trial. Nutrients, 15, Article No. 556. https://doi.org/10.3390/nu15030556
|
[34]
|
Salamun, V., Jensterle, M., Janez, A., et al. (2018) Liraglutide Increases IVF Pregnancy Rates in Obese PCOS Women with Poor Response to First-Line Reproductive Treatments: A Pilot Ran-domized Study. European Journal of Endocrinology, 179, 1-11. https://doi.org/10.1530/EJE-18-0175
|
[35]
|
Xing, C., Zhao, H., Zhang, J., et al. (2022) Effect of Metformin versus Metformin plus Liraglutide on Gonadal and Metabolic Profiles in Overweight Patients with Polycystic Ovary Syndrome. Frontiers in Endocrinology (Lausanne), 13, Article ID: 945609. https://doi.org/10.3389/fendo.2022.945609
|
[36]
|
Ma, R.L., Deng, Y., Wang, Y.F., et al. (2021) Short-Term Combined Treatment with Exenatide and Metformin for Overweight/Obese Women with Polycystic Ovary Syndrome. Chinese Medical Journal (England), 134, 2882-2889.
https://doi.org/10.1097/CM9.0000000000001712
|
[37]
|
Elkind-Hirsch, K.E., Chappell, N., Shaler, D., et al. (2022) Liraglutide 3 mg on Weight, Body Composition, and Hormonal and Metabolic Parameters in Women with Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled-Phase 3 Study. Fertility and Sterility, 118, 371-381. https://doi.org/10.1016/j.fertnstert.2022.04.027
|
[38]
|
Pruett, J.E., Torres, F.E., Everman, S.J., et al. (2021) Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome. International Journal of Molecular Sciences, 22, Article No. 2576.
https://doi.org/10.3390/ijms22052576
|
[39]
|
Cai, M., Shao, X., Xing, F., et al. (2022) Efficacy of Canagliflozin ver-sus Metformin in Women with Polycystic Ovary Syndrome: A Randomized, Open-Label, Noninferiority Trial. Diabetes, Obesity and Metabolism, 24, 312-320.
https://doi.org/10.1111/dom.14583
|
[40]
|
Zhang, J., Xing, C., Cheng, X., et al. (2022) Canagliflozin Combined with Metformin versus Metformin Monotherapy for Endocrine and Metabolic Profiles in Overweight and Obese Women with Polycystic Ovary Syndrome: A Single-Center, Open-Labeled Prospective Randomized Controlled Trial. Frontiers in Endocrinology (Lausanne), 13, Article ID: 1003238. https://doi.org/10.3389/fendo.2022.1003238
|